

"TEMPUS


Introduction to Tempus

JULY 30, 2022



An Intelligent Diagnostic helps doctors make better decisions, drug companies make better drugs, and patients live longer and healthier lives.

Tempus has moved quickly to establish a holistic solution for precision medicine in oncology



*We've partnered with $\frac{2}{3}$ of the top 20 oncology pharma companies, based on publicly available 2020 oncology segment revenue

Tempus xT Report

CLINICAL DECISION SUPPORT

Physicians receive a comprehensive report for each patient, making it easy to translate findings into personalized treatment decisions.

Our reports are embedded with Tempus Insights, patient-specific insights derived from real world evidence to empower physicians with the necessary data to improve patient care.

Date of Birth
04/20/1969Sex
FemalePhysician
Dr. BobInstitution
Chicago Cancer Center
(Streetsville)
123456789

TEMPUS | xT

648 gene panel

Tumor specimen:

Rectum

Collected 2/27/2021

Received 2/30/2021

Tumor Percentage: 30%

Normal specimen:

Blood

Collected 2/28/2021

Received 3/1/2021

GENOMIC VARIANTS

Somatic - Potentially Actionable

Variant Allele Fraction

SMAD4 p.G386Y Missense variant - LOF 16.7%

Somatic - Biologically Relevant

TP53 p.T256P Missense variant - LOF 43.1%

APC c.835-8A>G Splice region variant - LOF 16.8%

APC p.Q1294fs Frameshift - LOF 16.8%

TCF7L2 p.L359fs Frameshift - LOF 14.1%

CKS1B Copy number gain

MCL1 Copy number gain

RECQL4 Copy number gain

Germline - Pathogenic / Likely Pathogenic

No pathogenic variants were found in the limited set of genes on which we report.

Pertinent Negatives

No pathogenic single nucleotide variants, indels, or copy number changes found in:

KRAS BRAF NRAS

IMMUNOTHERAPY MARKERS

Tumor Mutational Burden

Microsatellite Instability Status

4.2 m/MB 57th percentile

Stable Equivocal High

ADDITIONAL INDICATORS

Unfavorable prognosis

SMAD4 p.G386Y Loss-of-function
Clinical research, Colorectal Cancer:
PMID 28267766

None of the therapies on this report were identified in the clinical notes received and abstracted by Tempus, which may not reflect the complete treatment history.

We're connected with **~50% of all Academic Medical Centers** in the United States and several **community institutions**.

We've partnered with **2/3 of the top 20 oncology pharma companies** and have **120+ biopharma partnerships**.



Patient Story

Flora

TEMPUS



CONFIDENTIAL

"TEMPUS

Appendix